Persistent Underrepresentation of Kidney Disease in Randomized, Controlled Trials of Cardiovascular Disease in the Contemporary Era

Rohit Maini¹, David B Wong², Daniel Addison^{3

4

5}, Elizabeth Chiang⁶, Steven D Weisbord⁷, Hani Jneid^{8

9}

Affiliations

¹ Division of Cardiology, Department of Medicine, Tulane University, New Orleans, Louisiana.
² Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
³ Cardiac Magnetic Resonance/Positron Emission Tomography/Computed Tomography Program, Department of Radiology, and.
⁴ Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Division of Cardiology, Department of Medicine, The Ohio State University Medical Center, Columbus, Ohio.
⁶ Division of Undergraduate Education, Johns Hopkins University, Baltimore, Maryland.
⁷ Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; and.
⁸ Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas; jneid@bcm.edu.
⁹ Division of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas.

Rohit Maini et al. J Am Soc Nephrol. 2018 Dec.

. 2018 Dec;29(12):2782-2786.

doi: 10.1681/ASN.2018070674. Epub 2018 Nov 2.

Rohit Maini¹, David B Wong², Daniel Addison^{3

4

5}, Elizabeth Chiang⁶, Steven D Weisbord⁷, Hani Jneid^{8

9}

¹ Division of Cardiology, Department of Medicine, Tulane University, New Orleans, Louisiana.
² Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
³ Cardiac Magnetic Resonance/Positron Emission Tomography/Computed Tomography Program, Department of Radiology, and.
⁴ Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Division of Cardiology, Department of Medicine, The Ohio State University Medical Center, Columbus, Ohio.
⁶ Division of Undergraduate Education, Johns Hopkins University, Baltimore, Maryland.
⁷ Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; and.
⁸ Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas; jneid@bcm.edu.
⁹ Division of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas.

No abstract available

Keywords: cardiovascular; cardiovascular disease; chronic kidney disease; chronic renal disease; randomized controlled trials.

References

1. Ganesha Babu G, Webber M, Providencia R, Kumar S, Gopalamurugan A, Rogers DP, et al. : Ventricular arrhythmia burden in patients with heart failure and cardiac resynchronization devices: The importance of renal function. J Cardiovasc Electrophysiol 27: 1328–1336, 2016 - PubMed
1. McClellan WM, Langston RD, Presley R: Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 15: 1912–1919, 2004 - PubMed
1. Charytan D, Kuntz RE: The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70: 2021–2030, 2006 - PMC - PubMed
1. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, et al. : Representation of patients with kidney disease in trials of cardiovascular interventions: An updated systematic review. JAMA Intern Med 176: 121–124, 2016 - PubMed
1. Coca SG, Krumholz HM, Garg AX, Parikh CR: Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296: 1377–1384, 2006 - PubMed